-
1
-
-
84874291673
-
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
-
Stenlöf K, Cefalu WT, Kim K-A et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 372-382
-
-
Stenlöf, K.1
Cefalu, W.T.2
Kim, K.-A.3
-
2
-
-
84891784200
-
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial
-
Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013; 36: 2508-2515.
-
(2013)
Diabetes Care
, vol.36
, pp. 2508-2515
-
-
Schernthaner, G.1
Gross, J.L.2
Rosenstock, J.3
-
3
-
-
84876311251
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
-
Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 463-473
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
-
4
-
-
84880543926
-
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial
-
Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013; 41: 72-84.
-
(2013)
Hosp Pract
, vol.41
, pp. 72-84
-
-
Bode, B.1
Stenlöf, K.2
Sullivan, D.3
Fung, A.4
Usiskin, K.5
-
5
-
-
84884167643
-
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
-
Cefalu WT, Leiter LA, Yoon K-H et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
-
(2013)
Lancet
, vol.382
, pp. 941-950
-
-
Cefalu, W.T.1
Leiter, L.A.2
Yoon, K.-H.3
-
6
-
-
84887997289
-
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
-
Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-2592.
-
(2013)
Diabetologia
, vol.56
, pp. 2582-2592
-
-
Lavalle-González, F.J.1
Januszewicz, A.2
Davidson, J.3
-
7
-
-
84888059660
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
-
Wilding JP, Charpentier G, Hollander P et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282.
-
(2013)
Int J Clin Pract
, vol.67
, pp. 1267-1282
-
-
Wilding, J.P.1
Charpentier, G.2
Hollander, P.3
-
8
-
-
84893299467
-
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
-
Stenlof K, Cefalu WT, Kim K-A et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163-175.
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 163-175
-
-
Stenlof, K.1
Cefalu, W.T.2
Kim, K.-A.3
-
9
-
-
84893482692
-
Canagliflozin (CANA) demonstrates durable glycemic improvements over 104 weeks versus glimepiride (GLIM) in subjects with type 2 diabetes mellitus (T2DM) on metformin (MET) (Abstract 65-LB)
-
Cefalu WT, Leiter LA, Yoon K-H et al. Canagliflozin (CANA) demonstrates durable glycemic improvements over 104 weeks versus glimepiride (GLIM) in subjects with type 2 diabetes mellitus (T2DM) on metformin (MET) (Abstract 65-LB). Diabetes 2013; 62(Suppl. 1): LB18.
-
(2013)
Diabetes
, vol.62
, pp. LB18
-
-
Cefalu, W.T.1
Leiter, L.A.2
Yoon, K.-H.3
-
10
-
-
67349189212
-
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
-
Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
-
(2009)
Kidney Int
, vol.75
, pp. 1272-1277
-
-
Bakris, G.L.1
Fonseca, V.A.2
Sharma, K.3
Wright, E.M.4
-
11
-
-
67649359913
-
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
-
Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009; 25: 671-681.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 671-681
-
-
Bays, H.1
-
12
-
-
84877710926
-
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus
-
Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: E867-871.
-
(2013)
J Clin Endocrinol Metab
, vol.98
, pp. E867-E871
-
-
Polidori, D.1
Sha, S.2
Ghosh, A.3
Plum-Mörschel, L.4
Heise, T.5
Rothenberg, P.6
-
13
-
-
84880320337
-
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus
-
Devineni D, Curtin CR, Polidori D et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601-610.
-
(2013)
J Clin Pharmacol
, vol.53
, pp. 601-610
-
-
Devineni, D.1
Curtin, C.R.2
Polidori, D.3
-
14
-
-
84861781220
-
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
-
Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
-
(2012)
Diabetes Care
, vol.35
, pp. 1232-1238
-
-
Rosenstock, J.1
Aggarwal, N.2
Polidori, D.3
-
15
-
-
84914135701
-
-
INVOKANA™ (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals
-
INVOKANA™ (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals, 2013.
-
(2013)
-
-
-
16
-
-
84880850027
-
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
-
Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-862.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 853-862
-
-
Lambers Heerspink, H.J.1
de Zeeuw, D.2
Wie, L.3
Leslie, B.4
List, J.5
-
17
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
-
(2012)
Diabetes Care
, vol.35
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
18
-
-
84876550739
-
Achievement of goals in U.S. diabetes care, 1999-2010
-
Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013; 368: 1613-1624.
-
(2013)
N Engl J Med
, vol.368
, pp. 1613-1624
-
-
Ali, M.K.1
Bullard, K.M.2
Saaddine, J.B.3
Cowie, C.C.4
Imperatore, G.5
Gregg, E.W.6
-
19
-
-
36248931664
-
The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition
-
Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13: 9-20.
-
(2007)
J Manag Care Pharm
, vol.13
, pp. 9-20
-
-
Atlas, S.A.1
-
20
-
-
0027372237
-
Determination of plasma volume with indocyanine green in man
-
Haller M, Akbulut C, Brechtelsbauer H et al. Determination of plasma volume with indocyanine green in man. Life Sci 1993; 53: 1597-1604.
-
(1993)
Life Sci
, vol.53
, pp. 1597-1604
-
-
Haller, M.1
Akbulut, C.2
Brechtelsbauer, H.3
-
21
-
-
33847695696
-
Technical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings
-
Jacob M, Conzen P, Finsterer U, Krafft A, Becker BF, Rehm M. Technical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings. J Appl Physiol 2007; 102: 1235-1242.
-
(2007)
J Appl Physiol
, vol.102
, pp. 1235-1242
-
-
Jacob, M.1
Conzen, P.2
Finsterer, U.3
Krafft, A.4
Becker, B.F.5
Rehm, M.6
-
22
-
-
0034997098
-
Determination of plasma volume by indocyanine green-validation of the method and use in patients after cardiopulmonary bypass
-
Menth-Meier SE, Imoberdorf R, Regli B, Kipfer B, Turgay M, Ballmer PE. Determination of plasma volume by indocyanine green-validation of the method and use in patients after cardiopulmonary bypass. Intensive Care Med 2001; 27: 925-929.
-
(2001)
Intensive Care Med
, vol.27
, pp. 925-929
-
-
Menth-Meier, S.E.1
Imoberdorf, R.2
Regli, B.3
Kipfer, B.4
Turgay, M.5
Ballmer, P.E.6
-
23
-
-
47649091315
-
Impact of the time window on plasma volume measurement with indocyanine green
-
Jacob M, Chappell D, Conzen P et al. Impact of the time window on plasma volume measurement with indocyanine green. Physiol Meas 2008; 29: 761-770.
-
(2008)
Physiol Meas
, vol.29
, pp. 761-770
-
-
Jacob, M.1
Chappell, D.2
Conzen, P.3
-
24
-
-
0024425016
-
Antipyrine, indocyanine green, and lorazepam determined in plasma by high-pressure liquid chromatography
-
Awni WM, Bakker LJ. Antipyrine, indocyanine green, and lorazepam determined in plasma by high-pressure liquid chromatography. Clin Chem 1989; 35: 2124-2126.
-
(1989)
Clin Chem
, vol.35
, pp. 2124-2126
-
-
Awni, W.M.1
Bakker, L.J.2
-
25
-
-
84904517986
-
Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method
-
in press
-
Polidori D, Rowley C. Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method. Theor Biol Med Model 2014 (in press).
-
(2014)
Theor Biol Med Model
-
-
Polidori, D.1
Rowley, C.2
-
26
-
-
0033574249
-
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group
-
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
-
(1999)
Ann Intern Med
, vol.130
, pp. 461-470
-
-
Levey, A.S.1
Bosch, J.P.2
Lewis, J.B.3
Greene, T.4
Rogers, N.5
Roth, D.6
-
27
-
-
0343364229
-
Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension
-
Gifford RWJ, Mattox VR, Orvis AL, Sones DA, Rosevear JW. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension. Circulation 1961; 24: 1197-1205.
-
(1961)
Circulation
, vol.24
, pp. 1197-1205
-
-
Gifford, R.W.J.1
Mattox, V.R.2
Orvis, A.L.3
Sones, D.A.4
Rosevear, J.W.5
-
28
-
-
0018891896
-
Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension
-
van Brummelen P, Schalekamp MA. Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. Acta Med Scand 1980; 207: 259-264.
-
(1980)
Acta Med Scand
, vol.207
, pp. 259-264
-
-
van Brummelen, P.1
Schalekamp, M.A.2
-
30
-
-
80052203917
-
Quantification of the effect of energy imbalance on bodyweight
-
Hall KD, Sacks G, Chandramohan D et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011; 378: 826-837.
-
(2011)
Lancet
, vol.378
, pp. 826-837
-
-
Hall, K.D.1
Sacks, G.2
Chandramohan, D.3
-
31
-
-
0018192282
-
Mechanism of antihypertensive effect of thiazide diuretics
-
Shah S, Khatri I, Freis ED. Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1978; 95: 611-618.
-
(1978)
Am Heart J
, vol.95
, pp. 611-618
-
-
Shah, S.1
Khatri, I.2
Freis, E.D.3
-
32
-
-
0018690043
-
Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus
-
Weidmann P, Beretta-Piccoli C, Keusch G et al. Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus. Am J Med 1979; 67: 779-784.
-
(1979)
Am J Med
, vol.67
, pp. 779-784
-
-
Weidmann, P.1
Beretta-Piccoli, C.2
Keusch, G.3
-
33
-
-
55949096514
-
SLC2A9 is a high-capacity urate transporter in humans
-
Caulfield MJ, Munroe PB, O'Neill D et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5: e197.
-
(2008)
PLoS Med
, vol.5
, pp. e197
-
-
Caulfield, M.J.1
Munroe, P.B.2
O'Neill, D.3
-
34
-
-
84899852101
-
Lower blood pressure (BP) with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) (Abstract 1077-P)
-
Weir MR, Januszewicz A, Gilbert R, Lavalle González F, Meininger G. Lower blood pressure (BP) with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) (Abstract 1077-P). Diabetes 2013; 62(Suppl. 1): A278.
-
(2013)
Diabetes
, vol.62
, Issue.1 SUPPL
, pp. A278
-
-
Weir, M.R.1
Januszewicz, A.2
Gilbert, R.3
Lavalle González, F.4
Meininger, G.5
|